Osteoarthritis of the knee (OAK) is increasing in prevalence, with patients being diagnosed earlier and living longer with pain. With the increasing impact of OAK, it becomes increasingly important for clinicians to have treatment options along the disease continuum to alleviate the joint pain that is a hallmark of OAK.
This program will introduce ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), the first and only FDA-approved intra-articular treatment for OAK pain utilizing extended-release microsphere technology.
Upon completion of this program, attendees will be able to:
Complimentary lunch is provided.
Space is limited, so please RSVP.
You must also be registered for the Orthopaedic Summit to attend.
If you are not registered for the Orthopaedic Summit, please Register Here.
Sponsored by Flexion
This session is presented by the sponsoring company and is not part of the Orthopaedic Summit accredited program.
2018 Ortho Summit